What is Cascade Testing for BRCA and HBOC Mutations?
At a Glance
Cascade testing is the process of offering targeted genetic testing to the blood relatives of someone diagnosed with a known genetic mutation, such as BRCA. This allows family members to learn their own cancer risk and take proactive steps with early screening and prevention strategies.
Finding out you carry a BRCA mutation naturally brings up a vital question: “What does this mean for my family?” Because these mutations are passed down through families, your biological relatives also have a chance of carrying the same genetic change. Cascade testing is the systematic medical process of offering genetic testing to the blood relatives of someone who has tested positive for a disease-causing genetic mutation [1][2]. This approach focuses on finding out if your parents, siblings, and children carry the exact same mutation, so they can take action to protect their health.
How Cascade Testing Works
When you are identified as having a pathogenic (disease-causing) mutation, you are known in genetics as the “proband” (the first person in a family to be tested). If you have a BRCA mutation, your first-degree relatives (parents, siblings, and children) each have a 50% chance of inheriting the same mutation. Clinical guidelines recommend that all first-degree and sometimes second-degree blood relatives (such as aunts, uncles, and grandparents) be offered genetic counseling and testing for your specific mutation [3][4].
Testing relatives is usually much faster and less expensive than your initial test. Instead of searching through all their genes, the laboratory looks only for the specific familial mutation that has already been identified in you [1][5].
The Importance of Testing Relatives
Knowing their genetic status gives your relatives the power to take proactive steps. Relatives who test positive can begin personalized cancer surveillance and risk-reduction strategies, which may include more intensive screenings (like breast MRIs) or risk-reducing surgeries [6][7]. For example, more frequent and detailed screenings can help detect cancers earlier when they are most treatable [8]. Relatives who test negative for the family’s known mutation can avoid unnecessary anxiety and intensive screenings, as their cancer risk is generally considered to be the same as the general population—unless there is a strong history of cancer on the other side of the family.
Despite these benefits, studies show that cascade testing is often underused, particularly among male relatives [9][10]. It is important to remember that men can also carry and pass on BRCA mutations, and they face increased risks for certain cancers, such as prostate and male breast cancer.
Ethical Considerations and Family Communication
Sharing your genetic test results with your family can be emotionally challenging. There is a delicate balance between your right to medical privacy and the potential “duty to warn” family members about a significant health risk [11]. In most cases, healthcare providers rely on you to communicate your test results to your relatives [9].
This conversation can bring up complex feelings. Some relatives may experience anxiety or distress about the possibility of having the mutation, while others may prefer not to know [11][12]. As a patient, you may feel a heavy burden to warn them, but it is also important to accept their boundaries if they refuse testing or do not want to know right now.
Fear of genetic discrimination in employment or health insurance can also be a significant barrier. In the United States, a federal law called the Genetic Information Nondiscrimination Act (GINA) protects individuals from being discriminated against by health insurers and employers based on genetic information.
Genetic counselors can be an invaluable resource during this time. They often provide tools like “Family Sharing Letters” that you can give to your relatives [13][14]. To open the conversation gently, you might use a sentence-starter like:
- “I recently had some genetic testing done to better understand my health, and my doctor suggested I share the results with you because they could affect your health too.”
When Should Adult Children Be Tested?
A major concern for parents is when to test their children. Because BRCA mutations primarily increase the risk of cancers that occur in adulthood, genetic testing is generally not recommended for minors. Testing is typically deferred to preserve the child’s autonomy, allowing them to make their own medical decisions when they reach adulthood [15].
The optimal timing for testing adult children is usually guided by when medical management would change. For BRCA carriers, intensive breast cancer screening and other interventions often begin around age 25 [6]. Therefore, early adulthood—often between the ages of 18 and 25—is typically when adult children are offered genetic counseling to discuss whether they want to proceed with testing.
Next Steps for Your Family
If you are ready to help your family get tested, here are the practical steps to share with them:
- Share your report: Give your relative a copy of your official genetic test report. Their doctor or genetic counselor will need this to order the exact, targeted test for your specific mutation.
- Consult a professional: Have your relative schedule an appointment with a genetic counselor or their primary care provider to discuss testing.
- Check insurance: Have them check with their health insurance. Because it is a targeted test for a known familial mutation and is recommended by clinical guidelines, it is usually covered by health insurance (especially for first-degree relatives), though co-pays and deductibles may apply [16][17].
Common questions in this guide
What is cascade testing for genetic mutations?
Which family members should get cascade testing for a BRCA mutation?
At what age should my children be tested for a BRCA mutation?
Does health insurance cover cascade testing for family members?
How do I help my family get tested for my genetic mutation?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Do you have a copy of my official genetic test report that I can give to my family members?
- 2.Can you refer my family members to a genetic counselor, or provide a 'Family Sharing Letter' to help me explain the results?
- 3.What is the specific name of my mutation that my relatives should ask their doctors to test for?
- 4.Are there any local or national resources you recommend for navigating difficult family conversations about genetic risks?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (17)
- 1
Disparities in gynecologic cancer genetics evaluation.
Hinchcliff EM, Bednar EM, Lu KH, Rauh-Hain JA
Gynecologic oncology 2019; (153(1)):184-191 doi:10.1016/j.ygyno.2019.01.024.
PMID: 30711300 - 2
Hereditary Breast and Ovarian Cancer Syndrome: Moving Beyond BRCA1 and BRCA2.
Hoang LN, Gilks BC
Advances in anatomic pathology 2018; (25(2)):85-95 doi:10.1097/PAP.0000000000000177.
PMID: 28914618 - 3
Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.
Konstantinopoulos PA, Norquist B, Lacchetti C, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020; (38(11)):1222-1245 doi:10.1200/JCO.19.02960.
PMID: 31986064 - 4
[Recommended Extension of Indication Criteria for Genetic Testing of BRCA1 and BRCA2 Mutations in Hereditary Breast and Ovarian Cancer Syndrome].
Foretová L, Macháčková E, Palácová M, et al.
Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 2016; (29 Suppl 1()):S9-13 doi:10.14735/amko2016s9.
PMID: 26691937 - 5
Recurrent large genomic rearrangements in BRCA1 and BRCA2 in an Irish case series.
McVeigh TP, Cody N, Carroll C, et al.
Cancer genetics 2017; (214-215()):1-8 doi:10.1016/j.cancergen.2017.02.001.
PMID: 28595730 - 6
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Daly MB, Pal T, Berry MP, et al.
Journal of the National Comprehensive Cancer Network : JNCCN 2021; (19(1)):77-102.
PMID: 33406487 - 7
The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer.
Hartmann LC, Lindor NM
The New England journal of medicine 2016; (374(5)):454-68 doi:10.1056/NEJMra1503523.
PMID: 26840135 - 8
Expanding the Genomic Landscape of HBOC and Cancer Risk Among Mutation Carriers.
Vietri MT, Della Pepa C, Caliendo G, et al.
International journal of molecular sciences 2025; (26(13)) doi:10.3390/ijms26135928.
PMID: 40649708 - 9
Uptake of Cascade Genetic Testing for Hereditary Breast and Ovarian Cancer: A Systematic Review and Meta-Analysis.
Ahsan MD, Chandler IR, Min S, et al.
Clinical obstetrics and gynecology 2024; (67(4)):702-710 doi:10.1097/GRF.0000000000000895.
PMID: 39431491 - 10
A Multi-Level Analysis of Barriers and Promoting Factors to Cascade Screening Uptake Among Male Relatives of BRCA1/2 Carriers: A Qualitative Study.
Ongaro G, Hamilton JG, Groner V, et al.
Psycho-oncology 2025; (34(5)):e70160 doi:10.1002/pon.70160.
PMID: 40374330 - 11
Psychological aspects, risk and protective factors related to BRCA genetic testing: a review of the literature.
Lombardi L, Bramanti SM, Babore A, et al.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2019; (27(10)):3647-3656 doi:10.1007/s00520-019-04918-7.
PMID: 31203511 - 12
Challenges of Genomic Testing for Hereditary Breast and Ovarian Cancers.
McAlarnen L, Stearns K, Uyar D
The application of clinical genetics 2021; (14()):1-9 doi:10.2147/TACG.S245021.
PMID: 33488111 - 13
Factors affecting the implementation of cascade testing of patients with BRCA1 or BRCA2 pathogenic germline variants in Japan.
Kiyozumi Y, Nishimura S, Kado N, et al.
Journal of genetic counseling 2025; (34(3)):e70055 doi:10.1002/jgc4.70055.
PMID: 40361302 - 14
The impact of a cascade testing video on recipients' knowledge, cognitive message processing, and affective reactions: A formative evaluation.
Aeilts AM, Carpenter KM, Hovick SR, et al.
Journal of genetic counseling 2021; (30(3)):656-664 doi:10.1002/jgc4.1345.
PMID: 33142025 - 15
Mother and Daughter Perspectives on Genetic Counseling and Testing of Adolescents for Hereditary Breast Cancer Risk.
Jennings C, Wynn J, Miguel C, et al.
The Journal of pediatrics 2022; (251()):113-119.e7 doi:10.1016/j.jpeds.2022.06.027.
PMID: 35777474 - 16
Association between Health Insurance Type and Genetic Testing and/or Counseling for Breast and Ovarian Cancer.
Mansur A, Zhang F, Lu CY
Journal of personalized medicine 2022; (12(8)) doi:10.3390/jpm12081263.
PMID: 36013212 - 17
The Clinical and Genetic Landscape of Hereditary Cancer: Experience from a Single Clinical Diagnostic Laboratory.
Tsoulos N, Agiannitopoulos K, Potska K, et al.
Cancer genomics & proteomics 2024; (21(5)):448-463 doi:10.21873/cgp.20463.
PMID: 39191493
This page provides information on cascade testing for educational purposes only. Always consult a certified genetic counselor or healthcare provider for personalized advice regarding genetic testing and family cancer risks.
Get notified when new evidence is published on Hereditary breast and/or ovarian cancer syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.